Resumen

LOPES, Cristina et al. Clinical protocol of evaluation of adult patients with atopic dermatitis treated with Dupilumab. Rev Port Imunoalergologia [online]. 2019, vol.27, n.2, pp.135-145. ISSN 0871-9721.

Atopic dermatitis is the most frequent inflammatory skin disease in developed countries and is often the first manifestation of allergic diseases. It usually appears until two years of age and when persisting into adulthood tends to be more severe. Its physiopathology is complex involving genetic and environmental factors. The treatment of severe forms is based on systemic immunosuppression and cyclosporine is the only drug of this class on label in Europe. Dupilumab is a monoclonal antibody anti-IL-4 /IL-13 indicated in the most severe forms of disease. This clinical protocol intends to establish clinical recommendations based on international guidelines for the use of dupilumab in adult patients with moderate to severe athopic dermatitis. It also approaches contraindications and special precautions proposing a schedule to monitorize treatment response

Palabras clave : Atopic dermatitis; dupilumab; monoclonal antibody; protocol; treatment.

        · resumen en Portugués     · texto en Portugués     · Portugués ( pdf )